Compare GMEX & PFSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GMEX | PFSA |
|---|---|---|
| Founded | 2005 | 2009 |
| Country | Australia | United States |
| Employees | 16 | N/A |
| Industry | Recreational Games/Products/Toys | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7M | 2.0M |
| IPO Year | 2023 | N/A |
| Metric | GMEX | PFSA |
|---|---|---|
| Price | $1.93 | $0.37 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 4.5M | 437.6K |
| Earning Date | 04-17-2026 | 04-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.24 | $0.05 |
| 52 Week High | $2.50 | $4.22 |
| Indicator | GMEX | PFSA |
|---|---|---|
| Relative Strength Index (RSI) | 60.83 | 36.11 |
| Support Level | $1.44 | $0.28 |
| Resistance Level | $2.10 | $0.41 |
| Average True Range (ATR) | 0.30 | 0.04 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 44.18 | 9.25 |
GMEX Robotics Corp is engaged in the design and deployment of AI-powered robotics and intelligent consumer technologies. The group operates in three business areas: Consumer and Commercial Robotics: Developing intuitive and interactive robots designed to assist with daily tasks, provide smart home integration, and offer new levels of convenience and connectivity to boost productivity; AI-Driven Hardware: Embedding artificial intelligence into physical products to create self-learning and adaptive user experiences; and Innovation & Ecosystem: Building a robust ecosystem of robotic products that communicate and evolve, powered by proprietary AI algorithms.
Profusa Inc is a clinical-stage digital health and medical technology company. The Company's technology enables the development of bioengineered sensors that are designed to become one with the body to detect and continuously transmit actionable, clinical-grade data for personal and medical use. The Company's first offering in the European Union, the Lumee Oxygen Platform, is designed to report reliable tissue oxygen levels at various regions of interest, both acutely and long-term. The Lumee Oxygen Platform has been designed for use in applications where monitoring of compromised tissue is beneficial, such as peripheral artery disease that results in narrowing of blood vessels and reduced blood flow to the lower limbs; chronic wounds that do not heal properly; and reconstructive surgery.